CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 188 enrolled
Drug / intervention
Linezolid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01561469
NCT01561469N/ACompleted

Multicenter, Retrospective, Observational Study to Evaluate Clinical and Economic Outcomes of Patients With MRSA Hospital-Acquired Pneumonia Treated With Linezolid Or Vancomycin

Pfizer·observational·Posted Mar 23, 2012·Updated Jul 10, 2014

In Brief

An observational study evaluating Linezolid and Vancomycin for Methicillin-Resistant Staphylococcus Aureus (MRSA) and Hospital-Acquired Pneumonia. Completed, enrolled 188 participants.

Detailed Summary

The objective of this study is to review the local management of patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia treated with vancomycin or linezolid with the goal to define if any difference exists among these antimicrobials in regard to clinical and economic outcomes.

Study Details

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 23, 2012
Enrollment StartNov 1, 2008
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 14.3 years ago

Interventions

Linezoliddrug

Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.

Vancomycindrug

Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.